U.S., June 13 -- ClinicalTrials.gov registry received information related to the study (NCT07645625) titled 'Pembrolizumab Registry for Outcomes and Treatment Evaluation in Cervical Cancer' on Jan. 05.
Brief Summary: This is a nationwide, multicenter, registry-based prospective cohort study to assess real-world effectiveness of treatment with a pembrolizumab containing regimen in persistent, recurrent, or metastatic cervical cancer. Patients in the observation cohort continue treatment according to standard of care. In the discontinuation cohort, patients discontinue their maintenance treatment with pembrolizumab (with or without discontinuation of bevacizumab). Patients may choose to discontinue pembrolizumab prematurely (with or without ...